Education
About Us
Working with TipRanks
Follow Us
Agenus (AGEN)
NASDAQ:AGEN
AGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.38 - $7.34
Previous CloseN/A
Volume199.21K
Average Volume (3M)427.36K
Market Cap
$125.86M
Enterprise Value$540.01M
Total Cash (Recent Filing)$9.53M
Total Debt (Recent Filing)$402.76M
Price to Earnings (P/E)―
Beta3.26
Next Earnings
Nov 11, 2025EPS Estimate
2.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding31,864,107
10 Day Avg. Volume472,500
30 Day Avg. Volume427,358
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap4.29
Enterprise Value/Revenue5.31
Enterprise Value/Gross Profit-1.12K
Enterprise Value/Ebitda-6.94
Forecast
1Y Price Target
$15.50Price Target Upside292.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe FDA approved the study design for the international Phase 3 trial, confirming that the patient population is representative of the US population.
Financial SupportThe partnership with Zydus Life Sciences provided a $91M infusion of operational capital, enabling Agenus to fully fund its upcoming trial.
Regulatory ApprovalBotensilimab + balstilimab (bot/bal) was granted compassionate access use from the French National Agency of Medicines and Health Products Safety for eligible patients with refractory microsatellite-stable metastatic colorectal cancer, providing an additional source of revenue to the company while generating real-world clinical evidence.
Bears Say
Regulatory ConcernsThe FDA reiterated that the demonstrated magnitude of treatment effect does not appear to meet the standard of reasonably likely to predict benefit.
Trial Design RisksGiven that about 70% of MSS mCRC patients have liver metastases, where outcomes tend to be worse, there is potential risk to achieving statistical significance in all-comers.
Agenus News
AGEN FAQ
What was Agenus’s price range in the past 12 months?
Agenus lowest stock price was $1.38 and its highest was $7.34 in the past 12 months.
What is Agenus’s market cap?
Agenus’s market cap is $125.86M.
When is Agenus’s upcoming earnings report date?
Agenus’s upcoming earnings report date is Nov 11, 2025 which is in 43 days.
How were Agenus’s earnings last quarter?
Agenus released its earnings results on Aug 11, 2025. The company reported -$1 earnings per share for the quarter, missing the consensus estimate of $2.42 by -$3.42.
Is Agenus overvalued?
According to Wall Street analysts Agenus’s price is currently Undervalued.
Does Agenus pay dividends?
Agenus does not currently pay dividends.
What is Agenus’s EPS estimate?
Agenus’s EPS estimate is 2.2.
How many shares outstanding does Agenus have?
Agenus has 31,864,107 shares outstanding.
What happened to Agenus’s price movement after its last earnings report?
Agenus reported an EPS of -$1 in its last earnings report, missing expectations of $2.42. Following the earnings report the stock price went down -11.042%.
Which hedge fund is a major shareholder of Agenus?
Among the largest hedge funds holding Agenus’s share is Oracle Investment Management Inc. It holds Agenus’s shares valued at 0.
Agenus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.50 (292.41% Upside)
$15.50 (292.41% Upside)
Blogger Sentiment
Neutral
AGEN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 127.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.59%
12-Months-Change
Fundamentals
Return on Equity
260.68%
Trailing 12-Months
Asset Growth
-36.66%
Trailing 12-Months
Company Description
Agenus
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
AGEN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted several positive developments, including strategic hires, promising BOT/BAL data, and multiple capital proposals which could strengthen the company's financial position. However, financial metrics such as a decreased cash balance and lower revenue compared to the previous year, alongside ongoing regulatory challenges, present notable challenges. The overall sentiment is cautiously optimistic as the highlights and lowlights are balanced.View all AGEN earnings summariesAGEN Stock 12 Month Forecast
Average Price Target
$15.50
▲(292.41% Upside)
Technical Analysis
Bio Green Med Solution
―
Fortress Biotech
―
Outlook Therapeutics
―
Quince Therapeutics
―
Immix Biopharma
―
Ownership Overview
2.59% Insiders
13.58% Mutual Funds
4.53% Other Institutional Investors
75.66% Public Companies and
Individual Investors